PCM
PROK icon

Prelude Capital Management’s ProKidney PROK Stock Holding History

Prelude Capital Management’s Portfolio PROK Stock Details PROK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,107
Closed -$21.7K – 1466
2026
Q1 		$21.7K Buy
+12,107
New +$25.7K ﹤0.01% 1160
2022
Q1 		– Sell
-61,432
Closed -$608K – 2140
2021
Q4 		$608K Hold
61,432
– – 0.02% 891
2021
Q3 		$602K Buy
+61,432
New +$605K 0.02% 799

Other funds holding PROK

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
AGP
Artia Global Partners Miami, Florida $542M AUM 206.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Prelude Capital Management's PROK Position: Q2 2026 in Review

Prelude Capital Management sold out of ProKidney (PROK) in Q2 2026, closing a stake of 12,107 shares — an estimated $21.7K sold.

Prelude Capital Management first reported a position in PROK in Q3 2021 and held it in 3 quarters. The position peaked at $608K in Q4 2021. 71 funds tracked by Wall St. Rank hold PROK as of Q2 2026.

  • Prelude Capital Management reported no remaining ProKidney position as of Q2 2026 after selling out during the quarter.
  • Prelude Capital Management sold 12,107 ProKidney shares in Q2 2026, an estimated $21.7K.
  • Prelude Capital Management first reported a position in ProKidney in Q3 2021 and held it in 3 quarters.
  • Prelude Capital Management's ProKidney position peaked at $608K in Q4 2021.
  • 71 funds tracked by Wall St. Rank held ProKidney as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.